GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

Jilin Province Xidian Pharmaceutical Sci-Tech Development Co 301130.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

23.52

-1.55%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Jilin Province Xidian Pharmaceutical Sci-Tech Development Co

Its shares trade on Shenzhen under the ticker 301130.SZ. It has been listed since 23 February 2022. In the fiscal year to 31 December 2025, it reported revenue of CN¥234.8m and net income of CN¥21.9m. At that date it held total assets of CN¥1.06bn and shareholders' equity of CN¥904.3m.

Jilin Province Xidian Pharmaceutical Sci-Tech Dev Co., Ltd. engages in the research, development and sale of chemical raw materials and preparations. The company is headquartered in Jilin, Jilin. The company went IPO on 2022-02-23. The firm's products cover the fields of anti anemia drugs, drugs for the treatment of mental disorders and the production of APIs, such as compound ferrous sulfate folic acid tablets, risperidone orally disintegrating tablets, escitalopram oxalate tablets, daphnetin capsules, sodium ferulate and ferrous fumarate.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
23 Feb 2022
Employees
194

Leadership

Pay as last reported

  • Mr. Jun ZhangChairman of the Board, General Manager, since 2017CN¥456,000
  • Mr. Si MengChief Financial Officer
  • Ms. Yinji ZhangDeputy General Manager, Secretary of the Board
  • Mr. Yonghong MengDeputy General Manager, Director, since 2017CN¥150,000
  • Mr. Yingxiu ShiDeputy General Manager, Director, since 2017CN¥150,000
  • Ms. Libo WangChief Quality OfficerCN¥150,000
  • Mr. Shiguo DingDirector
  • Ms. Shumin LiuDirector
  • Mr. Yanbin LiuDirector
  • Mr. Taigen ShenDirector
  • Mr. Baozhong WangDirector
  • Mr. Zhifeng WangDirector

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • 194 employees provide operational capacity
  • IPO in 2022-02-23 indicates market entry
  • Products include anti anemia drugs and mental disorder treatments

Weaknesses

  • No specific financial data provided for analysis
  • Limited product range mentioned in the source
  • Source description is untrusted and not to be followed

Opportunities

  • Growth potential in pharmaceutical sector in China
  • Expansion of product lines including APIs
  • Market demand for anti anemia and mental health drugs

Threats

  • Untrusted source description may affect credibility
  • Limited employee count may constrain scalability
  • IPO date suggests recent market entry with potential volatility

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.